AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

Core Insights - AstraZeneca and Daiichi Sankyo's drug Enhertu has demonstrated strong results in two pivotal studies focused on an early stage of a specific type of breast cancer [1] Group 1 - The drug Enhertu has shown promising efficacy in clinical trials, indicating potential for significant impact in breast cancer treatment [1]